Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Biosimulation Market, by Product
1.4.2 Europe Biosimulation Market, by Pricing Model
1.4.3 Europe Biosimulation Market, by End Use
1.4.4 Europe Biosimulation Market, by Application
1.4.5 Europe Biosimulation Market, by Deployment Model
1.4.6 Europe Biosimulation Market, by Therapeutic Area
1.4.7 Europe Biosimulation Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
Chapter 4. Competition Analysis – Global
4.1 Market Share Analysis, 2023
4.2 Strategies Deployed in Biosimulation Market
4.3 Porter Five Forces Analysis
Chapter 5. Europe Biosimulation Market by Product
5.1 Europe Software Market by Country
5.2 Europe Biosimulation Market by Software Type
5.2.1 Europe Molecular Modeling & Simulation Software Market by Country
5.2.2 Europe Clinical Trial Design Software Market by Country
5.2.3 Europe PK/PD Modeling and Simulation Software Market by Country
5.2.4 Europe Pbpk Modeling and Simulation Software Market by Country
5.2.5 Europe Toxicity Prediction Software Market by Country
5.2.6 Europe Other Software Type Market by Country
5.3 Europe Services Market by Country
5.4 Europe Biosimulation Market by Services Type
5.4.1 Europe Contract Services Market by Country
5.4.2 Europe Consulting Market by Country
5.4.3 Europe Other Services Type Market by Country
Chapter 6. Europe Biosimulation Market by Pricing Model
6.1 Europe License-based Model Market by Country
6.2 Europe Subscription-based Model Market by Country
6.3 Europe Service-based Model Market by Country
6.4 Europe Pay Per Use Model Market by Country
Chapter 7. Europe Biosimulation Market by End Use
7.1 Europe Life Sciences Companies Market by Country
7.2 Europe Academic Research Institutions Market by Country
7.3 Europe Other End Use Market by Country
Chapter 8. Europe Biosimulation Market by Application
8.1 Europe Drug Discovery & Development Market by Country
8.2 Europe Disease Modeling Market by Country
8.3 Europe Other Application Market by Country
Chapter 9. Europe Biosimulation Market by Deployment Model
9.1 Europe Cloud-based Market by Country
9.2 Europe On-premises Market by Country
9.3 Europe Hybrid Model Market by Country
Chapter 10. Europe Biosimulation Market by Therapeutic Area
10.1 Europe Oncology Market by Country
10.2 Europe Cardiovascular Disease Market by Country
10.3 Europe Infectious Disease Market by Country
10.4 Europe Neurological Disorders Market by Country
10.5 Europe Other Therapeutic Area Market by Country
Chapter 11. Europe Biosimulation Market by Country
11.1 Germany Biosimulation Market
11.1.1 Germany Biosimulation Market by Product
11.1.1.1 Germany Biosimulation Market by Software Type
11.1.1.2 Germany Biosimulation Market by Services Type
11.1.2 Germany Biosimulation Market by Pricing Model
11.1.3 Germany Biosimulation Market by End Use
11.1.4 Germany Biosimulation Market by Application
11.1.5 Germany Biosimulation Market by Deployment Model
11.1.6 Germany Biosimulation Market by Therapeutic Area
11.2 UK Biosimulation Market
11.2.1 UK Biosimulation Market by Product
11.2.1.1 UK Biosimulation Market by Software Type
11.2.1.2 UK Biosimulation Market by Services Type
11.2.2 UK Biosimulation Market by Pricing Model
11.2.3 UK Biosimulation Market by End Use
11.2.4 UK Biosimulation Market by Application
11.2.5 UK Biosimulation Market by Deployment Model
11.2.6 UK Biosimulation Market by Therapeutic Area
11.3 France Biosimulation Market
11.3.1 France Biosimulation Market by Product
11.3.1.1 France Biosimulation Market by Software Type
11.3.1.2 France Biosimulation Market by Services Type
11.3.2 France Biosimulation Market by Pricing Model
11.3.3 France Biosimulation Market by End Use
11.3.4 France Biosimulation Market by Application
11.3.5 France Biosimulation Market by Deployment Model
11.3.6 France Biosimulation Market by Therapeutic Area
11.4 Russia Biosimulation Market
11.4.1 Russia Biosimulation Market by Product
11.4.1.1 Russia Biosimulation Market by Software Type
11.4.1.2 Russia Biosimulation Market by Services Type
11.4.2 Russia Biosimulation Market by Pricing Model
11.4.3 Russia Biosimulation Market by End Use
11.4.4 Russia Biosimulation Market by Application
11.4.5 Russia Biosimulation Market by Deployment Model
11.4.6 Russia Biosimulation Market by Therapeutic Area
11.5 Spain Biosimulation Market
11.5.1 Spain Biosimulation Market by Product
11.5.1.1 Spain Biosimulation Market by Software Type
11.5.1.2 Spain Biosimulation Market by Services Type
11.5.2 Spain Biosimulation Market by Pricing Model
11.5.3 Spain Biosimulation Market by End Use
11.5.4 Spain Biosimulation Market by Application
11.5.5 Spain Biosimulation Market by Deployment Model
11.5.6 Spain Biosimulation Market by Therapeutic Area
11.6 Italy Biosimulation Market
11.6.1 Italy Biosimulation Market by Product
11.6.1.1 Italy Biosimulation Market by Software Type
11.6.1.2 Italy Biosimulation Market by Services Type
11.6.2 Italy Biosimulation Market by Pricing Model
11.6.3 Italy Biosimulation Market by End Use
11.6.4 Italy Biosimulation Market by Application
11.6.5 Italy Biosimulation Market by Deployment Model
11.6.6 Italy Biosimulation Market by Therapeutic Area
11.7 Rest of Europe Biosimulation Market
11.7.1 Rest of Europe Biosimulation Market by Product
11.7.1.1 Rest of Europe Biosimulation Market by Software Type
11.7.1.2 Rest of Europe Biosimulation Market by Services Type
11.7.2 Rest of Europe Biosimulation Market by Pricing Model
11.7.3 Rest of Europe Biosimulation Market by End Use
11.7.4 Rest of Europe Biosimulation Market by Application
11.7.5 Rest of Europe Biosimulation Market by Deployment Model
11.7.6 Rest of Europe Biosimulation Market by Therapeutic Area
Chapter 12. Company Profiles
12.1 Certara, Inc.
12.1.1 Company Overview
12.1.2 Financial Analysis
12.1.3 Regional Analysis
12.1.4 Research & Development Expenses
12.1.5 Recent strategies and developments:
12.1.5.1 Product Launches and Product Expansions:
12.1.5.2 Acquisition and Mergers:
12.1.6 SWOT Analysis
12.2 Dassault Systemes SE
12.2.1 Company Overview
12.2.2 Financial Analysis
12.2.3 Regional Analysis
12.2.4 Research & Development Expense
12.2.5 SWOT Analysis
12.3 Advanced Chemistry Development, Inc.
12.3.1 Company Overview
12.4 Genedata AG (Danaher Corporation)
12.4.1 Company Overview
12.4.2 Financial Analysis
12.4.3 Segmental and Regional Analysis
12.4.4 Research & Development Expense
12.4.5 Recent strategies and developments:
12.4.5.1 Partnerships, Collaborations, and Agreements:
12.5 Instem Group of Companies
12.5.1 Company Overview
12.6 Chemical Computing Group ULC
12.6.1 Company Overview
12.7 Simulations Plus, Inc.
12.7.1 Company Overview
12.7.2 Financial Analysis
12.7.3 Segmental and Regional Analysis
12.7.4 Research & Development Expenses
12.7.5 Recent strategies and developments:
12.7.5.1 Partnerships, Collaborations, and Agreements:
12.7.5.2 Product Launches and Product Expansions:
12.7.5.3 Acquisition and Mergers:
12.7.6 SWOT Analysis
12.8 Schrodinger, Inc.
12.8.1 Company Overview
12.8.2 Financial Analysis
12.8.3 Segmental and Regional Analysis
12.8.4 Research & Development Expenses
12.9 PPD, Inc. (Thermo Fisher Scientific, Inc.)
12.9.1 Company Overview
12.9.2 Financial Analysis
12.9.3 Segmental and Regional Analysis
12.9.4 Research & Development Expenses
12.10. Physiomics Plc
12.10.1 Company Overview
12.10.2 Financial Analysis
Unique Offerings 